SAM Holdings 9G2
SGD 0.02
-10.00% 0.00 Updated 29 Oct 2026, 11:58 SGT
Financials
Annual Report 2026
Explore the statements
9 tablesConsolidated Statement of Comprehensive Income (Group)
21 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, FY ended 30 June 2026 | 2025Group, FY ended 30 June 2025 | Source |
|---|---|---|---|
| Continuing operations | |||
| Revenue$ | 15,717,658 | 15,709,277 | PDF p. 113 |
| Other income$ | 537,167 | 864,628 | PDF p. 113 |
| Other gains$ | 75,447 | 117,512 | PDF p. 113 |
| Medical consultancy fees$ | (1,547,825) | (1,590,035) | PDF p. 113 |
| Repair and maintenance$ | (6,092,966) | (6,051,652) | PDF p. 113 |
| Purchase of inventories$ | (1,220,824) | (1,292,199) | PDF p. 113 |
| Depreciation of property, plant and equipment$ | (10,782,933) | (11,897,364) | PDF p. 113 |
| Amortisation of intangible assets$ | (7,346) | (9,146) | PDF p. 113 |
| Short-term rental of premises$ | (108,120) | (110,535) | PDF p. 113 |
| Impairment loss on trade receivables$ | – | (39,851) | PDF p. 113 |
| Impairment loss on property, plant and equipment$ | (178,030) | (2,467,854) | PDF p. 113 |
| Employee compensation$ | (10,156,650) | (11,035,486) | PDF p. 113 |
| Finance costs$ | (4,122,118) | (3,171,316) | PDF p. 113 |
| Other operating expenses$ | (5,999,855) | (6,072,757) | PDF p. 113 |
| Loss before tax$ | (23,886,395) | (27,046,778) | PDF p. 113 |
| Income tax expenses$ | – | – | PDF p. 113 |
| Loss after tax and total comprehensive loss from continuing operations for the year$ | (23,886,395) | (27,046,778) | PDF p. 113 |
| Discontinued operations | |||
| Loss from discontinued operations, net of tax$ | (10,661) | (7,404) | PDF p. 113 |
| Loss after tax and total comprehensive loss for the year$ | (23,897,056) | (27,054,182) | PDF p. 113 |
| Basic and diluted loss per share (cents) | |||
| From continuing operationscents per share | (2.01) | (2.57) | PDF p. 113 |
| Totalcents per share | (2.01) | (2.57) | PDF p. 113 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 113 ↗
** Amount less than 0.01 cents
Amounts in $ (Singapore dollars as printed '$').
Consolidated Statement of Financial Position (Group) as at 30 June 2026
29 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, as at 30 June 2026 | 2025Group, as at 30 June 2025 | Source |
|---|---|---|---|
| Equity | |||
| Share capital$ | 209,329,342 | 191,464,336 | PDF p. 111 |
| Other reserves$ | (1,769,096) | (5,077,737) | PDF p. 111 |
| Accumulated losses$ | (154,643,124) | (130,746,068) | PDF p. 111 |
| Total equity$ | 52,917,122 | 55,640,531 | PDF p. 111 |
| Non-current assets | |||
| Property, plant and equipment$ | 110,306,687 | 116,194,098 | PDF p. 111 |
| Intangible assets$ | 1,151 | 8,497 | PDF p. 111 |
| Other assets$ | 3,621,401 | 3,199,189 | PDF p. 111 |
| Subtotal$ | 113,929,239 | 119,401,784 | PDF p. 111 |
| Current assets | |||
| Inventories$ | 109,097 | 114,544 | PDF p. 111 |
| Trade and other receivables$ | 2,473,740 | 1,594,229 | PDF p. 111 |
| Other assets$ | 411,594 | 760,623 | PDF p. 111 |
| Cash and bank balances$ | 15,177,276 | 2,843,634 | PDF p. 111 |
| Subtotal$ | 18,171,707 | 5,313,030 | PDF p. 111 |
| Total assets$ | 132,100,946 | 124,714,814 | PDF p. 111 |
| Current liabilities | |||
| Trade and other payables$ | 12,674,541 | 5,838,500 | PDF p. 111 |
| Loans from shareholders$ | 17,435,811 | 2,093,463 | PDF p. 111 |
| Loan from non-related parties$ | – | 5,127,837 | PDF p. 111 |
| Bank borrowings$ | 1,409,847 | 2,245,572 | PDF p. 111 |
| Lease liabilities$ | 3,205,306 | 1,777,030 | PDF p. 111 |
| Provision for reinstatement costs$ | – | 265,052 | PDF p. 111 |
| Subtotal$ | 34,725,505 | 17,347,454 | PDF p. 111 |
| Net current liabilities$ | (16,553,798) | (12,034,424) | PDF p. 111 |
| Non-current liabilities | |||
| Loans from shareholders$ | 10,873,469 | 17,378,488 | PDF p. 111 |
| Bank borrowings$ | – | 1,410,346 | PDF p. 111 |
| Lease liabilities$ | 28,355,247 | 28,180,819 | PDF p. 111 |
| Provision for reinstatement costs$ | 5,229,603 | 4,757,176 | PDF p. 111 |
| Subtotal$ | 44,458,319 | 51,726,829 | PDF p. 111 |
| Total liabilities$ | 79,183,824 | 69,074,283 | PDF p. 111 |
| Net assets$ | 52,917,122 | 55,640,531 | PDF p. 111 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 111 ↗
Amounts in $ as printed.
Statement of Financial Position (Company) as at 30 June 2026
23 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Company, as at 30 June 2026 | 2025Company, as at 30 June 2025 | Source |
|---|---|---|---|
| Equity | |||
| Share capital$ | 209,329,342 | 191,464,336 | PDF p. 112 |
| Other reserves$ | (795,077) | (4,103,718) | PDF p. 112 |
| Accumulated losses$ | (69,964,077) | (55,679,741) | PDF p. 112 |
| Total equity$ | 138,570,188 | 131,680,877 | PDF p. 112 |
| Non-current assets | |||
| Investment in subsidiaries$ | 153,175,530 | 154,435,528 | PDF p. 112 |
| Intangible assets$ | 1,151 | 8,497 | PDF p. 112 |
| Subtotal$ | 153,176,681 | 154,444,025 | PDF p. 112 |
| Current assets | |||
| Other receivables$ | 4,581,314 | 4,501,605 | PDF p. 112 |
| Other assets$ | 4,800 | 10,441 | PDF p. 112 |
| Cash and bank balances$ | 13,050,603 | 1,528,763 | PDF p. 112 |
| Subtotal$ | 17,636,717 | 6,040,809 | PDF p. 112 |
| Total assets$ | 170,813,398 | 160,484,834 | PDF p. 112 |
| Current liabilities | |||
| Other payables$ | 2,524,083 | 548,251 | PDF p. 112 |
| Loans from shareholders$ | 17,435,811 | 2,093,463 | PDF p. 112 |
| Loan from a non-related party$ | – | 5,127,837 | PDF p. 112 |
| Bank borrowings$ | 1,409,847 | 2,245,572 | PDF p. 112 |
| Subtotal$ | 21,369,741 | 10,015,123 | PDF p. 112 |
| Net current liabilities$ | (3,733,024) | (3,974,314) | PDF p. 112 |
| Non-current liabilities | |||
| Loans from shareholders$ | 10,873,469 | 17,378,488 | PDF p. 112 |
| Bank borrowings$ | – | 1,410,346 | PDF p. 112 |
| Subtotal$ | 10,873,469 | 18,788,834 | PDF p. 112 |
| Total liabilities$ | 32,243,210 | 28,803,957 | PDF p. 112 |
| Net assets$ | 138,570,188 | 131,680,877 | PDF p. 112 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 112 ↗
Amounts in $ as printed.
Consolidated Statement of Comprehensive Income (Group)
21 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, FY ended 30 June 2026 | 2025Group, FY ended 30 June 2025 | Source |
|---|---|---|---|
| Continuing operations | |||
| Revenue$ | 15,717,658 | 15,709,277 | PDF p. 113 |
| Other income$ | 537,167 | 864,628 | PDF p. 113 |
| Other gains$ | 75,447 | 117,512 | PDF p. 113 |
| Medical consultancy fees$ | (1,547,825) | (1,590,035) | PDF p. 113 |
| Repair and maintenance$ | (6,092,966) | (6,051,652) | PDF p. 113 |
| Purchase of inventories$ | (1,220,824) | (1,292,199) | PDF p. 113 |
| Depreciation of property, plant and equipment$ | (10,782,933) | (11,897,364) | PDF p. 113 |
| Amortisation of intangible assets$ | (7,346) | (9,146) | PDF p. 113 |
| Short-term rental of premises$ | (108,120) | (110,535) | PDF p. 113 |
| Impairment loss on trade receivables$ | – | (39,851) | PDF p. 113 |
| Impairment loss on property, plant and equipment$ | (178,030) | (2,467,854) | PDF p. 113 |
| Employee compensation$ | (10,156,650) | (11,035,486) | PDF p. 113 |
| Finance costs$ | (4,122,118) | (3,171,316) | PDF p. 113 |
| Other operating expenses$ | (5,999,855) | (6,072,757) | PDF p. 113 |
| Loss before tax$ | (23,886,395) | (27,046,778) | PDF p. 113 |
| Income tax expenses$ | – | – | PDF p. 113 |
| Loss after tax and total comprehensive loss from continuing operations for the year$ | (23,886,395) | (27,046,778) | PDF p. 113 |
| Discontinued operations | |||
| Loss from discontinued operations, net of tax$ | (10,661) | (7,404) | PDF p. 113 |
| Total | |||
| Loss after tax and total comprehensive loss for the year$ | (23,897,056) | (27,054,182) | PDF p. 113 |
| Loss per share (cents) | |||
| From continuing operationscents per share | (2.01) | (2.57) | PDF p. 113 |
| Totalcents per share | (2.01) | (2.57) | PDF p. 113 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 113 ↗
** Amount less than 0.01 cents
No other comprehensive income items are presented; total comprehensive loss equals loss for the year.
Consolidated Statement of Changes in Equity (Group) – FY2026
10 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, Share capital | 2026Group, Capital reserve (Note 8(b)) | 2026Group, Accumulated losses | 2026Group, Total equity | Source |
|---|---|---|---|---|---|
| 2026 | |||||
| At 1 July 2025$ | 191,464,336 | (5,077,737) | (130,746,068) | 55,640,531 | PDF p. 114 |
| Gain on modification of loans from a shareholder$ | – | 86,337 | – | 86,337 | PDF p. 114 |
| Fair value gain on loans from a shareholder$ | – | 214,958 | – | 214,958 | PDF p. 114 |
| Conversion of loan from a non-related party to share capital$ | 5,240,418 | – | – | 5,240,418 | PDF p. 114 |
| Issuance of shares$ | 12,624,588 | – | – | 12,624,588 | PDF p. 114 |
| Warrants reserve for rights cum warrants issue$ | – | 3,007,346 | – | 3,007,346 | PDF p. 114 |
| Total transactions with owners, recognised directly in equity$ | 17,865,006 | 3,308,641 | – | 21,173,647 | PDF p. 114 |
| Loss for the year$ | – | – | (23,897,056) | (23,897,056) | PDF p. 114 |
| Total comprehensive loss for the year$ | – | – | (23,897,056) | (23,897,056) | PDF p. 114 |
| At 30 June 2026$ | 209,329,342 | (1,769,096) | (154,643,124) | 52,917,122 | PDF p. 114 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 114 ↗
Attributable to equity holders of the Company. No non-controlling interest column is presented.
Consolidated Statement of Changes in Equity (Group) – FY2025
9 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, Share capital | 2025Group, Share-based payment reserve (Note 8(a)) | 2025Group, Capital reserve (Note 8(b)) | 2025Group, Accumulated losses | 2025Group, Total equity | Source |
|---|---|---|---|---|---|---|
| 2025 | ||||||
| At 1 July 2024$ | 190,864,336 | 543,249 | (5,971,368) | (103,691,886) | 81,744,331 | PDF p. 115 |
| Share-based payment expense$ | – | 56,751 | – | – | 56,751 | PDF p. 115 |
| Issuance of shares$ | 600,000 | (600,000) | – | – | – | PDF p. 115 |
| Fair value gain on loans from a shareholder$ | – | – | 444,562 | – | 444,562 | PDF p. 115 |
| Gain on modification of loans from a shareholder$ | – | – | 449,069 | – | 449,069 | PDF p. 115 |
| Total transactions with owners, recognised directly in equity$ | 600,000 | (543,249) | 893,631 | – | 950,382 | PDF p. 115 |
| Loss for the year$ | – | – | – | (27,054,182) | (27,054,182) | PDF p. 115 |
| Total comprehensive loss for the year$ | – | – | – | (27,054,182) | (27,054,182) | PDF p. 115 |
| At 30 June 2025$ | 191,464,336 | – | (5,077,737) | (130,746,068) | 55,640,531 | PDF p. 115 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 115 ↗
Attributable to equity holders of the Company. No non-controlling interest column is presented.
Consolidated Statement of Cash Flows (Group) – operating and investing
26 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, FY ended 30 June 2026 | 2025Group, FY ended 30 June 2025 | Source |
|---|---|---|---|
| Cash flows from operating activities | |||
| Loss after tax$ | (23,897,056) | (27,054,182) | PDF p. 116 |
| Adjustments for | |||
| – Depreciation for property, plant and equipment$ | 10,782,933 | 11,897,364 | PDF p. 116 |
| – Amortisation of intangible assets$ | 7,346 | 9,146 | PDF p. 116 |
| – Gain on modification of loans from a non-related party$ | – | (97,088) | PDF p. 116 |
| – Gain on lease termination$ | (843) | – | PDF p. 116 |
| – Property, plant and equipment written off$ | – | 59 | PDF p. 116 |
| – Gain on disposal of property, plant and equipment$ | (69,999) | – | PDF p. 116 |
| – Impairment loss on trade receivables$ | – | 39,851 | PDF p. 116 |
| – Impairment loss on property, plant and equipment$ | 178,030 | 2,467,854 | PDF p. 116 |
| – Income from sublease$ | (359,490) | (287,019) | PDF p. 116 |
| – Interest income$ | (26,059) | (25,657) | PDF p. 116 |
| – Finance costs$ | 4,122,118 | 3,171,316 | PDF p. 116 |
| – Share-based payment expense$ | – | 56,751 | PDF p. 116 |
| – Stamp duty on loans from a shareholder$ | 15,350 | – | PDF p. 116 |
| Cash flows from operating activities | |||
| Operating cash flow before working capital changes$ | (9,247,670) | (9,821,605) | PDF p. 116 |
| Changes in working capital | |||
| – Inventories$ | 5,447 | (11,641) | PDF p. 116 |
| – Trade and other receivables$ | (871,729) | (511,008) | PDF p. 116 |
| – Other assets$ | (47,175) | 10,878 | PDF p. 116 |
| – Trade and other payables$ | 6,514,486 | (317,013) | PDF p. 116 |
| Cash flows from operating activities | |||
| Net cash used in operating activities$ | (3,646,641) | (10,650,389) | PDF p. 116 |
| Cash flows from investing activities | |||
| Purchases of property, plant and equipment$ | (488,798) | (147,785) | PDF p. 116 |
| Proceed from disposal of property, plant and equipment$ | 70,000 | – | PDF p. 116 |
| Proceeds from release of fixed deposit$ | 10,325 | – | PDF p. 116 |
| Sublease income received$ | 351,708 | 280,961 | PDF p. 116 |
| Interest received$ | 51 | 160 | PDF p. 116 |
| Net cash (used in)/generated from investing activities$ | (56,714) | 133,336 | PDF p. 116 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 116 ↗
Continued on next page (financing activities and closing cash).
Consolidated Statement of Cash Flows (Group) – financing and closing cash
14 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2026Group, FY ended 30 June 2026 | 2025Group, FY ended 30 June 2025 | Source |
|---|---|---|---|
| Cash flows from financing activities | |||
| Changes in restricted cash$ | (230,000) | (178,000) | PDF p. 117 |
| Proceeds from loans from shareholders$ | 7,200,000 | 12,000,000 | PDF p. 117 |
| Proceeds from loan from a non-related party$ | – | 5,000,000 | PDF p. 117 |
| Proceeds from issuance of share capital$ | 12,624,588 | – | PDF p. 117 |
| Proceeds from issuance of warrants$ | 3,007,346 | – | PDF p. 117 |
| Principal repayment of loans from shareholders$ | (91,580) | (29,617) | PDF p. 117 |
| Principal repayment of bank borrowings$ | (2,246,071) | (2,586,830) | PDF p. 117 |
| Principal payment of lease liabilities$ | (2,981,208) | (2,628,931) | PDF p. 117 |
| Interest paid on bank borrowings$ | (133,102) | (301,847) | PDF p. 117 |
| Interest paid on lease liabilities$ | (1,332,651) | (1,254,411) | PDF p. 117 |
| Net cash generated from financing activities$ | 15,817,322 | 10,020,364 | PDF p. 117 |
| Net change in cash | |||
| Net increase/(decrease) in cash and cash equivalents$ | 12,113,967 | (496,689) | PDF p. 117 |
| Cash and cash equivalents at beginning of financial year$ | 2,078,309 | 2,574,998 | PDF p. 117 |
| Cash and cash equivalents at end of financial year$ | 14,192,276 | 2,078,309 | PDF p. 117 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 117 ↗
Note A (pages 118-119) reconciles liabilities arising from financing activities; not extracted in detail.
Financial Highlights (five-year summary), Group
5 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2022Group, FY2022, S$ | 2023Group, FY2023, S$ | 2024Group, FY2024, S$ | 2025Group, FY2025, S$ | 2026Group, FY2026, S$ | Source |
|---|---|---|---|---|---|---|
| Operating Results | ||||||
| Revenue by yearS$ | 13,939,831 | 16,363,213 | 16,646,057 | 15,709,277 | 15,717,658 | PDF p. 19 |
| Loss before taxS$ | (12,425,187) | (18,071,610) | (37,445,084) | (27,054,182) | (23,897,056) | PDF p. 19 |
| Revenue by segment | ||||||
| Medical Diagnostics and TreatmentsS$ | 13,487,251 | 15,432,768 | 14,671,298 | 12,551,974 | 12,523,755 | PDF p. 19 |
| Radiation Therapy and Medical Oncology ServicesS$ | 321,129 | 800,883 | 1,974,759 | 3,157,303 | 3,193,903 | PDF p. 19 |
| Investment Property HoldingS$ | 131,451 | 129,562 | – | – | – | PDF p. 19 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 19 ↗
Page 19 also charts Revenue by year and Loss before tax with the same values; the segment total row is 13,939,831 16,363,213 16,646,057 15,709,277 15,717,658.
Where the money comes from
Segment information
By business
Segment information – year ended 30 June 2026 (business segments) 13 lines
| Item / unit | 2026Medical diagnostics and treatments | 2026Radiation therapy and medical oncology services | 2026Total for continuing operations | 2026Investment holding – discontinued operations | 2026Total for continuing and discontinued operations | Source |
|---|---|---|---|---|---|---|
| Segment revenue | ||||||
| Clinical and medical services fees$ | 11,893,720 | 3,193,903 | 15,087,623 | – | 15,087,623 | PDF p. 174 |
| Income from services to third parties$ | 630,035 | – | 630,035 | – | 630,035 | PDF p. 174 |
| Total revenue$ | 12,523,755 | 3,193,903 | 15,717,658 | – | 15,717,658 | PDF p. 174 |
| Reconciliations | ||||||
| EBITDA/(LBITDA)$ | 825,950 | (9,647,977) | (8,822,027) | (10,661) | (8,832,688) | PDF p. 174 |
| Interest income$ | 4,567 | 21,492 | 26,059 | – | 26,059 | PDF p. 174 |
| Impairment of property,$ | (178,030) | – | (178,030) | – | (178,030) | PDF p. 174 |
| Depreciation of property,$ | (2,129,332) | (8,653,601) | (10,782,933) | – | (10,782,933) | PDF p. 174 |
| Amortisation of intangible$ | – | (7,346) | (7,346) | – | (7,346) | PDF p. 174 |
| Finance costs$ | (358,606) | (3,763,512) | (4,122,118) | – | (4,122,118) | PDF p. 174 |
| Loss before and after tax$ | (1,835,451) | (22,050,944) | (23,886,395) | (10,661) | (23,897,056) | PDF p. 174 |
| Other segment items | ||||||
| Capital expenditure$ | 4,953,544 | 135,203 | 5,088,747 | – | 5,088,747 | PDF p. 174 |
| Segment assets$ | 10,120,306 | 121,980,640 | 132,100,946 | – | 132,100,946 | PDF p. 174 |
| Segment liabilities$ | 11,638,677 | 67,545,147 | 79,183,824 | – | 79,183,824 | PDF p. 174 |
Notes
The Group's non-current assets and revenue from external customers are principally located and generated in Singapore.
The Group does not have any major customers.
Segment information – year ended 30 June 2025 (business segments) 13 lines
| Item / unit | 2025Medical diagnostics and treatments | 2025Radiation therapy and medical oncology services | 2025Total for continuing operations | 2025Investment holding – discontinued operations | 2025Total for continuing and discontinued operations | Source |
|---|---|---|---|---|---|---|
| Segment revenue | ||||||
| Clinical and medical services fees$ | 12,520,850 | 3,157,303 | 15,678,153 | – | 15,678,153 | PDF p. 175 |
| Income from services to third parties$ | 31,124 | – | 31,124 | – | 31,124 | PDF p. 175 |
| Total revenue$ | 12,551,974 | 3,157,303 | 15,709,277 | – | 15,709,277 | PDF p. 175 |
| Reconciliations | ||||||
| EBITDA/(LBITDA)$ | 543,150 | (10,069,905) | (9,526,755) | (7,404) | (9,534,159) | PDF p. 175 |
| Interest income$ | 4,477 | 21,180 | 25,657 | – | 25,657 | PDF p. 175 |
| Impairment of property,$ | (2,467,854) | – | (2,467,854) | – | (2,467,854) | PDF p. 175 |
| Depreciation of property,$ | (3,241,972) | (8,655,392) | (11,897,364) | – | (11,897,364) | PDF p. 175 |
| Amortisation of intangible$ | – | (9,146) | (9,146) | – | (9,146) | PDF p. 175 |
| Finance costs$ | (232,121) | (2,939,195) | (3,171,316) | – | (3,171,316) | PDF p. 175 |
| Loss before and after tax$ | (5,394,320) | (21,652,458) | (27,046,778) | (7,404) | (27,054,182) | PDF p. 175 |
| Other segment items | ||||||
| Capital expenditure$ | 108,378 | 39,407 | 147,785 | – | 147,785 | PDF p. 175 |
| Segment assets$ | 6,691,709 | 117,996,844 | 124,688,553 | 26,261 | 124,714,814 | PDF p. 175 |
| Segment liabilities$ | 7,960,953 | 61,107,730 | 69,068,683 | 5,600 | 69,074,283 | PDF p. 175 |
Notes
The Group's non-current assets and revenue from external customers are principally located and generated in Singapore (note 29 text, page 173).
Debt
Borrowings
Lease liabilities maturity analysis
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Maturity analysis | |||
| Less than 1 year$ | 4,434,466 | 2,939,377 | PDF p. 146 |
| Between 1 and 2 years$ | 4,391,813 | 2,785,631 | PDF p. 146 |
| More than 2 and less than 5 years$ | 8,940,176 | 8,511,046 | PDF p. 146 |
| More than 5 years$ | 21,505,808 | 24,407,561 | PDF p. 146 |
| Total undiscounted (unlabelled subtotal)$ | 39,272,263 | 38,643,615 | PDF p. 146 |
| Less: Future interest charges$ | (7,711,710) | (8,685,766) | PDF p. 146 |
| Lease liabilities (net, unlabelled)$ | 31,560,553 | 29,957,849 | PDF p. 146 |
| Analysed as | |||
| Current$ | 3,205,306 | 1,777,030 | PDF p. 146 |
| Non-current$ | 28,355,247 | 28,180,819 | PDF p. 146 |
Notes
Total cash outflow for all leases in the year was $4,423,399 (2025: $3,998,321). Subtotal rows have no printed label.
Borrowing notes 6 tables
Bank borrowings – current and non-current
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Current | |||
| Bank borrowings$ | 1,409,847 | 2,245,572 | PDF p. 164 |
| Non-current | |||
| Bank borrowings$ | – | 1,410,346 | PDF p. 164 |
| Total | |||
| Total bank borrowings$ | 1,409,847 | 3,655,918 | PDF p. 164 |
Notes
Term loan (TL) of $1,409,847 (2025: $3,308,166) drawn for loans refinancing; repayable over 36 months; secured by fixed and floating charge over all present and future assets of the Company, AMO and PTPL, including the Proton beam therapy System, among other security.
Temporary bridging loan (TBL) of $Nil (2025: $347,752); repayable over 60 months; secured by legal charge over all shares in AHP, AMI, AMO, PTPL and AMR, corporate guarantees and other security.
Weighted average effective interest rate of the Group's bank borrowings is 4.06% (2025: 5.66%) per annum.
Carrying amount approximates fair value. Bank borrowings are denominated in Singapore Dollar.
Bank borrowings are subject to gearing ratio, tangible net worth and DSCR covenants (Note 31, page 182).
Bank borrowings – contractual repricing dates
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Interest rate exposure / contractual repricing | |||
| 3 months or less$ | 1,409,847 | 3,655,918 | PDF p. 164 |
Note 30(a)(ii) Variable rate financial liabilities
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Financial liabilities – Variable rate | |||
| Loans from shareholders$ | 28,309,280 | 19,471,951 | PDF p. 177 |
| Bank borrowings$ | 1,409,847 | 3,308,166 | PDF p. 177 |
| Total variable rate$ | 29,719,127 | 22,780,117 | PDF p. 177 |
Notes
Borrowings at variable rates without effective hedges are denominated mainly in SGD. A 1% change in rates would change loss before tax by $297,191 (2025: $282,557) for Group and Company.
Loans from shareholders
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Current | |||
| Loan from a shareholder (i)$ | 2,221,405 | 2,093,463 | PDF p. 160 |
| Loan from a shareholder (ii)$ | 4,440,471 | – | PDF p. 160 |
| Loan from a shareholder (iii)$ | 1,381,849 | – | PDF p. 160 |
| Loan from a shareholder (iv)$ | 6,351,450 | – | PDF p. 160 |
| Loan from a shareholder (vii)$ | 3,040,636 | – | PDF p. 160 |
| Total current$ | 17,435,811 | 2,093,463 | PDF p. 160 |
| Non-current | |||
| Loan from a shareholder (ii)$ | – | 4,118,725 | PDF p. 160 |
| Loan from a shareholder (iii)$ | 6,628,611 | 7,361,643 | PDF p. 160 |
| Loan from a shareholder (iv)$ | – | 5,898,120 | PDF p. 160 |
| Loan from a shareholder (v)$ | 1,536,528 | – | PDF p. 160 |
| Loan from a shareholder (vi)$ | 1,526,843 | – | PDF p. 160 |
| Loan from a shareholder (viii)$ | 1,181,487 | – | PDF p. 160 |
| Total non-current$ | 10,873,469 | 17,378,488 | PDF p. 160 |
| Total | |||
| Total loans from shareholders$ | 28,309,280 | 19,471,951 | PDF p. 160 |
Notes
Loans (i)-(vi): interest at 0.02% plus Maybank Base Lending Rate per annum; loans (vii) and (viii) at 8% per annum (loan (viii) revised to 10% per annum for the extended period).
Loan (i) revised maturity 31 December 2026; loans (iii) revised maturities 30 June 2027, 31 July 2027 and 27 September 2027; loan (viii) revised maturity 13 November 2027; loans (ii), (iv), (v), (vi) repayable within two years from drawdown; loan (vii) $1,800,000 within one year, $1,200,000 settled July 2026.
All loans from shareholders are denominated in Singapore Dollar. Not stated as secured in the note.
Loan from a non-related party
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Current | |||
| Loan from a non-related party$ | – | 5,127,837 | PDF p. 162 |
Notes
$5,000,000 loan, converted into ordinary shares on 15 October 2025 (Note 7). Denominated in Singapore Dollar.
Statement of financial position – borrowings and lease lines, Group
| Item / unit | 2026$ | 2025$ | Source |
|---|---|---|---|
| Current liabilities | |||
| Loans from shareholders$ | 17,435,811 | 2,093,463 | PDF p. 111 |
| Loan from non-related parties$ | – | 5,127,837 | PDF p. 111 |
| Bank borrowings$ | 1,409,847 | 2,245,572 | PDF p. 111 |
| Lease liabilities$ | 3,205,306 | 1,777,030 | PDF p. 111 |
| Non-current liabilities | |||
| Loans from shareholders$ | 10,873,469 | 17,378,488 | PDF p. 111 |
| Bank borrowings$ | – | 1,410,346 | PDF p. 111 |
| Lease liabilities$ | 28,355,247 | 28,180,819 | PDF p. 111 |
Notes
Printed label on page 111 for the 2025 non-related loan line is 'Loan from non-related parties' (statement says 'Loans from non-related parties' in the same row; quote as read: 'Loan from non-related parties'). Group-only table; Company statement on page 112 has same loans and bank borrowings but no lease liabilities.
Payout
Dividends & distributions
Dividend policy
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Provision 11.6 | The Company does not have a formal dividend policy. The form, frequency and amount of dividends will depend on the Group’s earnings, financial position, results of operations, capital needs, plans for expansion, and other factors as the Board may deem appropriate. | FY2026 | PDF p. 80 |
Dividends declared and proposed
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Dividend recommendation FY2026 | The Board has not recommended any dividend for FY2026 as the Company recorded a loss for FY2026. | FY2026 | PDF p. 80 |
Extracted from Annual Report 2026 and checked against the cited pages; see the original report for full context.
Auditor’s report
Audit & risk signals
Audit opinion
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Audit firm | Foo Kon Tan LLP | Group and Company, FY ended 30 June 2026 | PDF p. 110 |
| Engagement partner | Ho Teik Tiong | Group and Company, FY2026 | PDF p. 110 |
| Disclaimer of Opinion | We do not express an opinion on the accompanying consolidated financial statements of the Group and the statement of financial position of the Company. | Group and Company, FY ended 30 June 2026 | PDF p. 106 |
| Basis for Disclaimer of Opinion (i) Opening balances and comparative information | We are unable to obtain sufficient appropriate audit evidence to determine whether the opening balances in respect of property, plant and equipment and the Company’s investment in a subsidiary as at 1 July 2025 are appropriately stated. | Group and Company, FY2026 | PDF p. 107 |
| Basis for Disclaimer of Opinion (iii) Impairment of property, plant and equipment | Consequently, we are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the property, plant and equipment is necessary. | Group, as at 30 June 2026 | PDF p. 108 |
| Basis for Disclaimer of Opinion (iv) Impairment of the Company’s investment in a subsidiary | Consequently, we are unable to determine whether any adjustment to the accompanying financial statements in relation to the carrying value of the cost of investment in subsidiaries relating to PTPL is necessary. | Company, as at 30 June 2026 | PDF p. 109 |
Going concern
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Basis for Disclaimer of Opinion (ii) Going concern | The above conditions indicate the existence of material uncertainties that may cast significant doubt on the ability of the Group and of the Company to continue as going concerns. | Group and Company, FY2026 | PDF p. 107 |
| 2.2 Going concern | For the financial year ended 30 June 2026, the Group reported a loss after tax of $23,886,395 (2025: $27,046,778) from continuing operations and net cash used in operating activities amounted to $3,646,641 (2025: $10,650,389). | Group, FY2026 with FY2025 comparatives | PDF p. 122 |
Extracted from Annual Report 2026 and checked against the cited pages; see the original report for full context.
How to read these figures
Group and parent company or bank figures are labelled separately. Parentheses indicate negative amounts; a dash and NA retain the report’s notation.
Comparative figures follow Annual Report 2026, including retrospective adjustments. Adjusted and reported earnings may have different definitions; refer to each statement’s notes.
These tables show the available extracted figures. The original annual report contains the full statements, notes and definitions.